UNSPSC 51401705: Olanzapine

This classification denotes an antipsychotic agent with the molecular formula C17H20N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N7U69T4SZR, chemically known as 10h-thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- but generally known as olanzapine, which bears US NIH Compound Identifier 4585. European Medicines Agency schedules Olanzapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09426MIG.

UNSPSC 51401705 Olanzapine is a Commodity code representing pharmaceutical products purchased by state and local health systems, but recent state and local opportunities show minimal activity directly aligned with this specific drug. The three recent solicitations in the block—Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's direct-to-manufacturer prescription RFI, and MMCAP's generic multi-source pharmaceuticals cooperative contract—address broader pharmacy benefit and emergency-response drug categories rather than olanzapine specifically. State and local buyers under related pharmaceutical codes typically include county health departments, state human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The issuing bodies across these opportunities span county-level health procurement (Seminole County, Florida), state-level pharmacy benefit administration (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance).

Recent activity shows purchasing spread across Florida, Texas, Minnesota, and Oregon, with cooperative purchasing arrangements serving the widest geographic footprint. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, with response due July 26, 2023, sought 1,900 units of naloxone annually through quarterly deliveries, illustrating county-level emergency pharmaceutical procurement. The Texas Health and Human Services Commission's RFI (HHS0017013), posted April 3, 2026, gathered market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026, with questions due February 18, 2026, and proposals due March 26, 2026, solicited manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through three authorized wholesalers, with awards effective July 1, 2026. The code shows limited recent state and local procurement activity specifically for olanzapine; broader pharmaceutical procurement is active but driven by cooperative purchasing, generic drug aggregation, and emergency-response initiatives rather than single-drug specialty formulations.